Roger S Lo

Title(s)Professor, Medicine
SchoolMedicine
vCardDownload vCard
    Other Positions
    Title(s)Professor, Molecular and Medical Pharmacology


    Collapse Research 
    Collapse Research Activities and Funding
    Understanding PD-L1/L2 protein regulation, detection and signaling to predict melanoma therapeutic sensitivity
    NIH R21CA255837Mar 1, 2021 - Feb 28, 2023
    Role: Principal Investigator
    Exploiting Drug Addiction to Improve the Efficacy of MAPK Pathway Targeted Therapy in BRAF and NRAS Mutant Melanoma
    NIH R21CA215910Dec 11, 2017 - Nov 30, 2020
    Role: Principal Investigator
    Combinatorial Targeting of Epigenomic and Microenvironmental Pathways to Suppress MAPK Inhibitor Resistance in Melanoma
    NIH R01CA176111Aug 7, 2013 - Jun 30, 2024
    Role: Principal Investigator
    Augmenting Melanoma Response to B-Raf V600E Targeting
    NIH K22CA151638Aug 19, 2010 - Jul 31, 2013
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Plasticity of extrachromosomal and intrachromosomal BRAF amplifications in overcoming targeted therapy dosage challenges. Cancer Discov. 2021 Dec 20. Song K, Minami JK, Huang A, Dehkordi SR, Lomeli SH, Luebeck J, Goodman MH, Moriceau G, Krijgsman O, Dharanipragada P, Ridgley T, Crosson WP, Salazar J, Pazol E, Karin G, Jayaraman R, Balanis NG, Alhani S, Sheu K, Ten Hoeve J, Palermo A, Motika SE, Senaratne TN, Paraiso KH, Hergenrother PJ, Rao PN, Multani AS, Peeper DS, Bafna V, Lo RS, Graeber TG. PMID: 34930786.
      View in: PubMed   Mentions:
    2. Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma. Cell Rep Med. 2021 Oct 19; 2(10):100411. Liu S, Knochelmann HM, Lomeli SH, Hong A, Richardson M, Yang Z, Lim RJ, Wang Y, Dumitras C, Krysan K, Timmers C, Romeo MJ, Krieg C, O'Quinn EC, Horton JD, Dubinett SM, Paulos CM, Neskey DM, Lo RS. PMID: 34755131; PMCID: PMC8561238.
      View in: PubMed   Mentions:
    3. Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma. Cell Rep Med. 2021 Oct 19; 2(10):100426. Knochelmann HM, Horton JD, Liu S, Armeson K, Kaczmar JM, Wyatt MM, Richardson MS, Lomeli SH, Xiong Y, Graboyes EM, Lentsch EJ, Hornig JD, Skoner J, Stalcup S, Spampinato MV, Garrett-Mayer E, O'Quinn EC, Timmers CD, Romeo MJ, Wrangle JM, Young MRI, Rubinstein MP, Day TA, Lo RS, Paulos CM, Neskey DM. PMID: 34755137; PMCID: PMC8561313.
      View in: PubMed   Mentions:
    4. Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy. Cancer Cell. 2021 Aug 18. Wang Y, Liu S, Yang Z, Algazi AP, Lomeli SH, Wang Y, Othus M, Hong A, Wang X, Randolph CE, Jones AM, Bosenberg MW, Byrum SD, Tackett AJ, Lopez H, Yates C, Solit DB, Ribas A, Piva M, Moriceau G, Lo RS. PMID: 34416167.
      View in: PubMed   Mentions:    Fields:    
    5. Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd-5th, 2020, Italy). J Transl Med. 2021 06 30; 19(1):278. Ascierto PA, Blank C, Dummer R, Ernstoff MS, Ferrone S, Fox BA, Gajewski TF, Garbe C, Hwu P, Kalinski P, Krogsgaard M, Lo RS, Luke JJ, Neyns B, Postow MA, Quezada SA, Teng MWL, Trinchieri G, Testori A, Caracò C, Osman I, Puzanov I, Thurin M. PMID: 34193182; PMCID: PMC8243582.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    6. Wound healing with topical BRAF inhibitor therapy in a diabetic model suggests tissue regenerative effects. PLoS One. 2021; 16(6):e0252597. Escuin-Ordinas H, Liu Y, Sun L, Hugo W, Dimatteo R, Huang RR, Krystofinski P, Azhdam A, Lee J, Comin-Anduix B, Cochran AJ, Lo RS, Segura T, Scumpia PO, Ribas A. PMID: 34161353; PMCID: PMC8221471.
      View in: PubMed   Mentions:    Fields:    
    7. SPRED1 deletion confers resistance to MAPK inhibition in melanoma. J Exp Med. 2021 03 01; 218(3). Ablain J, Liu S, Moriceau G, Lo RS, Zon LI. PMID: 33306107; PMCID: PMC7927430.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    8. Author Correction: Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy. Nat Med. 2021 Feb; 27(2):355. Pérez-Guijarro E, Yang HH, Araya RE, El Meskini R, Michael HT, Vodnala SK, Marie KL, Smith C, Chin S, Lam KC, Thorkelsson A, Iacovelli AJ, Kulaga A, Fon A, Michalowski AM, Hugo W, Lo RS, Restifo NP, Sharan SK, Van Dyke T, Goldszmid RS, Weaver Ohler Z, Lee MP, Day CP, Merlino G. PMID: 33514948.
      View in: PubMed   Mentions:    Fields:    
    9. Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity. Cancer Discov. 2021 03; 11(3):714-735. Hong A, Piva M, Liu S, Hugo W, Lomeli SH, Zoete V, Randolph CE, Yang Z, Wang Y, Lee JJ, Lo SJ, Sun L, Vega-Crespo A, Garcia AJ, Shackelford DB, Dubinett SM, Scumpia PO, Byrum SD, Tackett AJ, Donahue TR, Michielin O, Holmen SL, Ribas A, Moriceau G, Lo RS. PMID: 33318037; PMCID: PMC7933113.
      View in: PubMed   Mentions: 2     Fields:    
    10. Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial. Nat Med. 2020 10; 26(10):1564-1568. Algazi AP, Othus M, Daud AI, Lo RS, Mehnert JM, Truong TG, Conry R, Kendra K, Doolittle GC, Clark JI, Messino MJ, Moore DF, Lao C, Faller BA, Govindarajan R, Harker-Murray A, Dreisbach L, Moon J, Grossmann KF, Ribas A. PMID: 33020646; PMCID: PMC8063889.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    11. Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy). J Transl Med. 2020 09 07; 18(1):346. Ascierto PA, Puzanov I, Agarwala SS, Blank C, Carvajal RD, Demaria S, Dummer R, Ernstoff M, Ferrone S, Fox BA, Gajewski TF, Garbe C, Hwu P, Lo RS, Long GV, Luke JJ, Osman I, Postow MA, Sullivan RJ, Taube JM, Trinchieri G, Zarour HM, Caracò C, Thurin M. PMID: 32894202; PMCID: PMC7487701.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    12. Trying for a BRAF Slam Dunk. Cancer Discov. 2020 05; 10(5):640-642. Ribas A, Lo RS. PMID: 32357967; PMCID: PMC7363198.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    13. Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy. Nat Med. 2020 05; 26(5):781-791. Pérez-Guijarro E, Yang HH, Araya RE, El Meskini R, Michael HT, Vodnala SK, Marie KL, Smith C, Chin S, Lam KC, Thorkelsson A, Iacovelli AJ, Kulaga A, Fon A, Michalowski AM, Hugo W, Lo RS, Restifo NP, Sharan SK, Van Dyke T, Goldszmid RS, Weaver Ohler Z, Lee MP, Day CP, Merlino G. PMID: 32284588; PMCID: PMC8482620.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    14. Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression. Cell Rep. 2019 Dec 10; 29(11):3766. Garcia-Diaz A, Shin DS, Moreno BH, Saco J, Escuin-Ordinas H, Rodriguez GA, Zaretsky JM, Sun L, Hugo W, Wang X, Parisi G, Saus CP, Torrejon DY, Graeber TG, Comin-Anduix B, Hu-Lieskovan S, Damoiseaux R, Lo RS, Ribas A. PMID: 31825850.
      View in: PubMed   Mentions: 17     Fields:    
    15. The great debate at "Immunotherapy Bridge 2018", Naples, November 29th, 2018. J Immunother Cancer. 2019 08 15; 7(1):221. Ascierto PA, Butterfield LH, Demaria S, Ferris RL, Freeman GJ, Lo RS, Mantovani A, Nathan P, Hamid O, Politi K, Puzanov I. PMID: 31416487; PMCID: PMC6696687.
      View in: PubMed   Mentions:
    16. Melanoma to Vitiligo: The Melanocyte in Biology & Medicine-Joint Montagna Symposium on the Biology of Skin/PanAmerican Society for Pigment Cell Research Annual Meeting. J Invest Dermatol. 2020 02; 140(2):269-274. Leachman SA, Hornyak TJ, Barsh G, Bastian BC, Brash DE, Cleaver JE, Cooper CD, D'Orazio JA, Fujita M, Holmen SL, Indra AK, Kraemer KH, Le Poole IC, Lo RS, Lund AW, Manga P, Pavan WJ, Setaluri V, Stemwedel CE, Kulesz-Martin MF. PMID: 31348921; PMCID: PMC6981008.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    17. Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy). J Transl Med. 2019 07 22; 17(1):234. Ascierto PA, Agarwala SS, Botti G, Budillon A, Davies MA, Dummer R, Ernstoff M, Ferrone S, Formenti S, Gajewski TF, Garbe C, Hamid O, Lo RS, Luke JJ, Michielin O, Palmieri G, Zitvogel L, Marincola FM, Masucci G, Caracò C, Thurin M, Puzanov I. PMID: 31331337; PMCID: PMC6647284.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    18. The Prognostic Significance of Low-Frequency Somatic Mutations in Metastatic Cutaneous Melanoma. Front Oncol. 2018; 8:584. Zhao X, Little P, Hoyle AP, Pegna GJ, Hayward MC, Ivanova A, Parker JS, Marron DL, Soloway MG, Jo H, Salazar AH, Papakonstantinou MP, Bouchard DM, Jefferys SR, Hoadley KA, Ollila DW, Frank JS, Thomas NE, Googe PB, Ezzell AJ, Collichio FA, Lee CB, Earp HS, Sharpless NE, Hugo W, Wilmott JS, Quek C, Waddell N, Johansson PA, Thompson JF, Hayward NK, Mann GJ, Lo RS, Johnson DB, Scolyer RA, Hayes DN, Moschos SJ. PMID: 30662871; PMCID: PMC6329304.
      View in: PubMed   Mentions: 3  
    19. The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression. Clin Cancer Res. 2018 07 15; 24(14):3366-3376. Huang L, Malu S, McKenzie JA, Andrews MC, Talukder AH, Tieu T, Karpinets T, Haymaker C, Forget MA, Williams LJ, Wang Z, Mbofung RM, Wang ZQ, Davis RE, Lo RS, Wargo JA, Davies MA, Bernatchez C, Heffernan T, Amaria RN, Korkut A, Peng W, Roszik J, Lizée G, Woodman SE, Hwu P. PMID: 29496759.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    20. High-Speed Live-Cell Interferometry: A New Method for Quantifying Tumor Drug Resistance and Heterogeneity. Anal Chem. 2018 03 06; 90(5):3299-3306. Huang D, Leslie KA, Guest D, Yeshcheulova O, Roy IJ, Piva M, Moriceau G, Zangle TA, Lo RS, Teitell MA, Reed J. PMID: 29381859.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    21. Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma. Cancer Discov. 2018 01; 8(1):74-93. Hong A, Moriceau G, Sun L, Lomeli S, Piva M, Damoiseaux R, Holmen SL, Sharpless NE, Hugo W, Lo RS. PMID: 28923912; PMCID: PMC6456057.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansAnimals
    22. Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation. Cancer Discov. 2017 11; 7(11):1248-1265. Song C, Piva M, Sun L, Hong A, Moriceau G, Kong X, Zhang H, Lomeli S, Qian J, Yu CC, Damoiseaux R, Kelley MC, Dahlman KB, Scumpia PO, Sosman JA, Johnson DB, Ribas A, Hugo W, Lo RS. PMID: 28864476; PMCID: PMC6668729.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansAnimalsCells
    23. Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression. Cell Rep. 2017 05 09; 19(6):1189-1201. Garcia-Diaz A, Shin DS, Moreno BH, Saco J, Escuin-Ordinas H, Rodriguez GA, Zaretsky JM, Sun L, Hugo W, Wang X, Parisi G, Saus CP, Torrejon DY, Graeber TG, Comin-Anduix B, Hu-Lieskovan S, Damoiseaux R, Lo RS, Ribas A. PMID: 28494868; PMCID: PMC6420824.
      View in: PubMed   Mentions: 378     Fields:    Translation:HumansCells
    24. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell. 2017 01 26; 168(3):542. Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G, Seja E, Lomeli S, Kong X, Kelley MC, Sosman JA, Johnson DB, Ribas A, Lo RS. PMID: 28129544.
      View in: PubMed   Mentions: 83     Fields:    
    25. Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. Cancer Discov. 2017 02; 7(2):188-201. Shin DS, Zaretsky JM, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A, Grasso CS, Hugo W, Sandoval S, Torrejon DY, Palaskas N, Rodriguez GA, Parisi G, Azhdam A, Chmielowski B, Cherry G, Seja E, Berent-Maoz B, Shintaku IP, Le DT, Pardoll DM, Diaz LA, Tumeh PC, Graeber TG, Lo RS, Comin-Anduix B, Ribas A. PMID: 27903500; PMCID: PMC5296316.
      View in: PubMed   Mentions: 355     Fields:    Translation:HumansCells
    26. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015. J Transl Med. 2016 11 15; 14(1):313. Ascierto PA, Agarwala S, Botti G, Cesano A, Ciliberto G, Davies MA, Demaria S, Dummer R, Eggermont AM, Ferrone S, Fu YX, Gajewski TF, Garbe C, Huber V, Khleif S, Krauthammer M, Lo RS, Masucci G, Palmieri G, Postow M, Puzanov I, Silk A, Spranger S, Stroncek DF, Tarhini A, Taube JM, Testori A, Wang E, Wargo JA, Yee C, Zarour H, Zitvogel L, Fox BA, Mozzillo N, Marincola FM, Thurin M. PMID: 27846884; PMCID: PMC5111349.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimals
    27. Regional glutamine deficiency in tumours promotes dedifferentiation through inhibition of histone demethylation. Nat Cell Biol. 2016 10; 18(10):1090-101. Pan M, Reid MA, Lowman XH, Kulkarni RP, Tran TQ, Liu X, Yang Y, Hernandez-Davies JE, Rosales KK, Li H, Hugo W, Song C, Xu X, Schones DE, Ann DK, Gradinaru V, Lo RS, Locasale JW, Kong M. PMID: 27617932; PMCID: PMC5536113.
      View in: PubMed   Mentions: 104     Fields:    Translation:HumansAnimalsCells
    28. JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma. Cell Discov. 2016; 2:16028. Titz B, Lomova A, Le A, Hugo W, Kong X, Ten Hoeve J, Friedman M, Shi H, Moriceau G, Song C, Hong A, Atefi M, Li R, Komisopoulou E, Ribas A, Lo RS, Graeber TG. PMID: 27648299; PMCID: PMC5012007.
      View in: PubMed   Mentions: 22  
    29. Cutaneous wound healing through paradoxical MAPK activation by BRAF inhibitors. Nat Commun. 2016 08 01; 7:12348. Escuin-Ordinas H, Li S, Xie MW, Sun L, Hugo W, Huang RR, Jiao J, de-Faria FM, Realegeno S, Krystofinski P, Azhdam A, Komenan SM, Atefi M, Comin-Anduix B, Pellegrini M, Cochran AJ, Modlin RL, Herschman HR, Lo RS, McBride WH, Segura T, Ribas A. PMID: 27476449; PMCID: PMC4974650.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimalsCells
    30. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. N Engl J Med. 2016 Sep 01; 375(9):819-29. Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Abril-Rodriguez G, Sandoval S, Barthly L, Saco J, Homet Moreno B, Mezzadra R, Chmielowski B, Ruchalski K, Shintaku IP, Sanchez PJ, Puig-Saus C, Cherry G, Seja E, Kong X, Pang J, Berent-Maoz B, Comin-Anduix B, Graeber TG, Tumeh PC, Schumacher TN, Lo RS, Ribas A. PMID: 27433843; PMCID: PMC5007206.
      View in: PubMed   Mentions: 858     Fields:    Translation:HumansCells
    31. Corrigendum: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature. 2016 Sep 08; 537(7619):254. Kaur A, Webster MR, Marchbank K, Behera R, Ndoye A, Kugel CH, Dang VM, Appleton J, O'Connell MP, Cheng P, Valiga AA, Morissette R, McDonnell NB, Ferrucci L, Kossenkov AV, Meeth K, Tang HY, Yin X, Wood WH, Lehrmann E, Becker KG, Flaherty KT, Frederick DT, Wargo JA, Cooper ZA, Tetzlaff MT, Hudgens C, Aird KM, Zhang R, Xu X, Liu Q, Bartlett E, Karakousis G, Eroglu Z, Lo RS, Chan M, Menzies AM, Long GV, Johnson DB, Sosman J, Schilling B, Schadendorf D, Speicher DW, Bosenberg M, Ribas A, Weeraratna AT. PMID: 27383789.
      View in: PubMed   Mentions: 4     Fields:    
    32. The state of melanoma: challenges and opportunities. Pigment Cell Melanoma Res. 2016 07; 29(4):404-16. Merlino G, Herlyn M, Fisher DE, Bastian BC, Flaherty KT, Davies MA, Wargo JA, Curiel-Lewandrowski C, Weber MJ, Leachman SA, Soengas MS, McMahon M, Harbour JW, Swetter SM, Aplin AE, Atkins MB, Bosenberg MW, Dummer R, Gershenwald JE, Halpern AC, Herlyn D, Karakousis GC, Kirkwood JM, Krauthammer M, Lo RS, Long GV, McArthur G, Ribas A, Schuchter L, Sosman JA, Smalley KS, Steeg P, Thomas NE, Tsao H, Tueting T, Weeraratna A, Xu G, Lomax R, Martin A, Silverstein S, Turnham T, Ronai ZA. PMID: 27087480; PMCID: PMC5228487.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCells
    33. sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature. 2016 Apr 14; 532(7598):250-4. Kaur A, Webster MR, Marchbank K, Behera R, Ndoye A, Kugel CH, Dang VM, Appleton J, O'Connell MP, Cheng P, Valiga AA, Morissette R, McDonnell NB, Ferrucci L, Kossenkov AV, Meeth K, Tang HY, Yin X, Wood WH, Lehrmann E, Becker KG, Flaherty KT, Frederick DT, Wargo JA, Cooper ZA, Tetzlaff MT, Hudgens C, Aird KM, Zhang R, Xu X, Liu Q, Bartlett E, Karakousis G, Eroglu Z, Lo RS, Chan M, Menzies AM, Long GV, Johnson DB, Sosman J, Schilling B, Schadendorf D, Speicher DW, Bosenberg M, Ribas A, Weeraratna AT. PMID: 27042933; PMCID: PMC4833579.
      View in: PubMed   Mentions: 112     Fields:    Translation:HumansAnimalsCells
    34. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell. 2016 Mar 24; 165(1):35-44. Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G, Seja E, Lomeli S, Kong X, Kelley MC, Sosman JA, Johnson DB, Ribas A, Lo RS. PMID: 26997480; PMCID: PMC4808437.
      View in: PubMed   Mentions: 818     Fields:    Translation:HumansCells
    35. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014. J Transl Med. 2015 Nov 30; 13:374. Ascierto PA, Atkins M, Bifulco C, Botti G, Cochran A, Davies M, Demaria S, Dummer R, Ferrone S, Formenti S, Gajewski TF, Garbe C, Khleif S, Kiessling R, Lo R, Lorigan P, Arthur GM, Masucci G, Melero I, Mihm M, Palmieri G, Parmiani G, Puzanov I, Romero P, Schilling B, Seliger B, Stroncek D, Taube J, Tomei S, Zarour HM, Testori A, Wang E, Galon J, Ciliberto G, Mozzillo N, Marincola FM, Thurin M. PMID: 26619946; PMCID: PMC4665874.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    36. Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. Eur J Cancer. 2015 Dec; 51(18):2792-9. Johnson DB, Menzies AM, Zimmer L, Eroglu Z, Ye F, Zhao S, Rizos H, Sucker A, Scolyer RA, Gutzmer R, Gogas H, Kefford RF, Thompson JF, Becker JC, Berking C, Egberts F, Loquai C, Goldinger SM, Pupo GM, Hugo W, Kong X, Garraway LA, Sosman JA, Ribas A, Lo RS, Long GV, Schadendorf D. PMID: 26608120; PMCID: PMC4666799.
      View in: PubMed   Mentions: 97     Fields:    Translation:HumansCells
    37. Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance. Cell. 2015 Sep 10; 162(6):1271-85. Hugo W, Shi H, Sun L, Piva M, Song C, Kong X, Moriceau G, Hong A, Dahlman KB, Johnson DB, Sosman JA, Ribas A, Lo RS. PMID: 26359985; PMCID: PMC4821508.
      View in: PubMed   Mentions: 197     Fields:    Translation:HumansCells
    38. Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination. Proc Natl Acad Sci U S A. 2015 Sep 01; 112(35):10995-1000. Sanborn JZ, Chung J, Purdom E, Wang NJ, Kakavand H, Wilmott JS, Butler T, Thompson JF, Mann GJ, Haydu LE, Saw RP, Busam KJ, Lo RS, Collisson EA, Hur JS, Spellman PT, Cleaver JE, Gray JW, Huh N, Murali R, Scolyer RA, Bastian BC, Cho RJ. PMID: 26286987; PMCID: PMC4568214.
      View in: PubMed   Mentions: 50     Fields:    Translation:Humans
    39. Vemurafenib resistance reprograms melanoma cells towards glutamine dependence. J Transl Med. 2015 Jul 03; 13:210. Hernandez-Davies JE, Tran TQ, Reid MA, Rosales KR, Lowman XH, Pan M, Moriceau G, Yang Y, Wu J, Lo RS, Kong M. PMID: 26139106; PMCID: PMC4490757.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansAnimalsCells
    40. Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma. Mol Cancer. 2015 Jul 02; 14:128. Wong DJ, Robert L, Atefi MS, Lassen A, Avarappatt G, Cerniglia M, Avramis E, Tsoi J, Foulad D, Graeber TG, Comin-Anduix B, Samatar A, Lo RS, Ribas A. PMID: 26134498; PMCID: PMC4488977.
      View in: PubMed   Mentions: 3     Fields:    
    41. Therapy-induced tumour secretomes promote resistance and tumour progression. Nature. 2015 Apr 16; 520(7547):368-72. Obenauf AC, Zou Y, Ji AL, Vanharanta S, Shu W, Shi H, Kong X, Bosenberg MC, Wiesner T, Rosen N, Lo RS, Massagué J. PMID: 25807485; PMCID: PMC4507807.
      View in: PubMed   Mentions: 162     Fields:    Translation:HumansAnimalsCells
    42. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. Cancer Cell. 2015 Feb 09; 27(2):240-56. Moriceau G, Hugo W, Hong A, Shi H, Kong X, Yu CC, Koya RC, Samatar AA, Khanlou N, Braun J, Ruchalski K, Seifert H, Larkin J, Dahlman KB, Johnson DB, Algazi A, Sosman JA, Ribas A, Lo RS. PMID: 25600339; PMCID: PMC4326539.
      View in: PubMed   Mentions: 120     Fields:    Translation:HumansCells
    43. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. Nat Commun. 2014 Dec 15; 5:5712. Müller J, Krijgsman O, Tsoi J, Robert L, Hugo W, Song C, Kong X, Possik PA, Cornelissen-Steijger PD, Geukes Foppen MH, Kemper K, Goding CR, McDermott U, Blank C, Haanen J, Graeber TG, Ribas A, Lo RS, Peeper DS. PMID: 25502142; PMCID: PMC4428333.
      View in: PubMed   Mentions: 206     Fields:    Translation:HumansAnimalsCells
    44. Antitumor activity of the ERK inhibitor SCH772984 [corrected] against BRAF mutant, NRAS mutant and wild-type melanoma. Mol Cancer. 2014 Aug 20; 13:194. Wong DJ, Robert L, Atefi MS, Lassen A, Avarappatt G, Cerniglia M, Avramis E, Tsoi J, Foulad D, Graeber TG, Comin-Anduix B, Samatar A, Lo RS, Ribas A. PMID: 25142146; PMCID: PMC4155088.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCells
    45. Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors. Nat Commun. 2014 May 22; 5:3901. Marusiak AA, Edwards ZC, Hugo W, Trotter EW, Girotti MR, Stephenson NL, Kong X, Gartside MG, Fawdar S, Hudson A, Breitwieser W, Hayward NK, Marais R, Lo RS, Brognard J. PMID: 24849047; PMCID: PMC4046110.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansAnimalsCells
    46. Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Discov. 2014 Apr; 4(4):423-33. Parmenter TJ, Kleinschmidt M, Kinross KM, Bond ST, Li J, Kaadige MR, Rao A, Sheppard KE, Hugo W, Pupo GM, Pearson RB, McGee SL, Long GV, Scolyer RA, Rizos H, Lo RS, Cullinane C, Ayer DE, Ribas A, Johnstone RW, Hicks RJ, McArthur GA. PMID: 24469106; PMCID: PMC4110245.
      View in: PubMed   Mentions: 106     Fields:    Translation:HumansCells
    47. Detecting mechanisms of acquired BRAF inhibitor resistance in melanoma. Methods Mol Biol. 2014; 1102:163-74. Lo RS, Shi H. PMID: 24258979.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    48. COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors. Mol Oncol. 2014 Mar; 8(2):250-60. Escuin-Ordinas H, Atefi M, Fu Y, Cass A, Ng C, Huang RR, Yashar S, Comin-Anduix B, Avramis E, Cochran AJ, Marais R, Lo RS, Graeber TG, Herschman HR, Ribas A. PMID: 24345644; PMCID: PMC3943738.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansAnimals
    49. A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov. 2014 Jan; 4(1):69-79. Shi H, Hong A, Kong X, Koya RC, Song C, Moriceau G, Hugo W, Yu CC, Ng C, Chodon T, Scolyer RA, Kefford RF, Ribas A, Long GV, Lo RS. PMID: 24265152; PMCID: PMC3893054.
      View in: PubMed   Mentions: 81     Fields:    Translation:HumansCells
    50. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 2014 Jan; 4(1):80-93. Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB, Kelley MC, Kefford RF, Chmielowski B, Glaspy JA, Sosman JA, van Baren N, Long GV, Ribas A, Lo RS. PMID: 24265155; PMCID: PMC3936420.
      View in: PubMed   Mentions: 376     Fields:    Translation:HumansCells
    51. Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012". J Transl Med. 2013 Jun 03; 11:137. Ascierto PA, Grimaldi AM, Acquavella N, Borgognoni L, Calabrò L, Cascinelli N, Cesano A, Del Vecchio M, Eggermont AM, Faries M, Ferrone S, Fox BA, Gajewski TF, Galon J, Gnjatic S, Gogas H, Kashani-Sabet M, Kaufman HL, Larkin J, Lo RS, Mantovani A, Margolin K, Melief C, McArthur G, Palmieri G, Puzanov I, Ribas A, Seliger B, Sosman J, Suenaert P, Tarhini AA, Trinchieri G, Vidal-Vanaclocha F, Wang E, Ciliberto G, Mozzillo N, Marincola FM, Thurin M. PMID: 23731854; PMCID: PMC3681569.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimals
    52. Meeting report from the Society for Melanoma Research 2012 Congress, Hollywood, California. Pigment Cell Melanoma Res. 2013 Jul; 26(4):E1-7. Lo RS, Ribas A, Long GV, Ballotti R, Berger M, Willy H, Gibney GT, Bosenberg M, Bernstein E, Villanueva J, Smalley KS. PMID: 23551976.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimals
    53. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol. 2013 May 10; 31(14):1767-74. Trunzer K, Pavlick AC, Schuchter L, Gonzalez R, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Kim KB, Weber JS, Hersey P, Long GV, Lawrence D, Ott PA, Amaravadi RK, Lewis KD, Puzanov I, Lo RS, Koehler A, Kockx M, Spleiss O, Schell-Steven A, Gilbert HN, Cockey L, Bollag G, Lee RJ, Joe AK, Sosman JA, Ribas A. PMID: 23569304.
      View in: PubMed   Mentions: 150     Fields:    Translation:HumansCellsCTClinical Trials
    54. Polymer nanofiber-embedded microchips for detection, isolation, and molecular analysis of single circulating melanoma cells. Angew Chem Int Ed Engl. 2013 Mar 18; 52(12):3379-83. Hou S, Zhao L, Shen Q, Yu J, Ng C, Kong X, Wu D, Song M, Shi X, Xu X, OuYang WH, He R, Zhao XZ, Lee T, Brunicardi FC, Garcia MA, Ribas A, Lo RS, Tseng HR. PMID: 23436302; PMCID: PMC3807678.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansCells
    55. Melanoma prognostics and personalized therapeutics at a crossroad. J Invest Dermatol. 2013 Feb; 133(2):292-5. Lo RS. PMID: 23318787.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    56. Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine. . 2012 Dec; 11(12):2704-8. Wilmott JS, Tembe V, Howle JR, Sharma R, Thompson JF, Rizos H, Lo RS, Kefford RF, Scolyer RA, Long GV. PMID: 22962325.
      View in: PubMed   Mentions: 28  Translation:Humans
    57. Topical 5-fluorouracil elicits regressions of BRAF inhibitor-induced cutaneous squamous cell carcinoma. J Invest Dermatol. 2013 Jan; 133(1):274-6. Viros A, Hayward R, Martin M, Yashar S, Yu CC, Sanchez-Laorden B, Zambon A, Niculescu-Duvaz D, Springer C, Lo RS, Marais R. PMID: 22895366.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    58. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet. 2012 Sep; 44(9):1006-14. Krauthammer M, Kong Y, Ha BH, Evans P, Bacchiocchi A, McCusker JP, Cheng E, Davis MJ, Goh G, Choi M, Ariyan S, Narayan D, Dutton-Regester K, Capatana A, Holman EC, Bosenberg M, Sznol M, Kluger HM, Brash DE, Stern DF, Materin MA, Lo RS, Mane S, Ma S, Kidd KK, Hayward NK, Lifton RP, Schlessinger J, Boggon TJ, Halaban R. PMID: 22842228; PMCID: PMC3432702.
      View in: PubMed   Mentions: 501     Fields:    Translation:Humans
    59. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012 Jul 26; 487(7408):500-4. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, Davis A, Mongare MM, Gould J, Frederick DT, Cooper ZA, Chapman PB, Solit DB, Ribas A, Lo RS, Flaherty KT, Ogino S, Wargo JA, Golub TR. PMID: 22763439; PMCID: PMC3711467.
      View in: PubMed   Mentions: 719     Fields:    Translation:HumansCells
    60. MDM4 is a key therapeutic target in cutaneous melanoma. Nat Med. 2012 Aug; 18(8):1239-47. Gembarska A, Luciani F, Fedele C, Russell EA, Dewaele M, Villar S, Zwolinska A, Haupt S, de Lange J, Yip D, Goydos J, Haigh JJ, Haupt Y, Larue L, Jochemsen A, Shi H, Moriceau G, Lo RS, Ghanem G, Shackleton M, Bernal F, Marine JC. PMID: 22820643; PMCID: PMC3744207.
      View in: PubMed   Mentions: 130     Fields:    Translation:HumansAnimalsCells
    61. Glucose deprivation activates a metabolic and signaling amplification loop leading to cell death. Mol Syst Biol. 2012 Jun 26; 8:589. Graham NA, Tahmasian M, Kohli B, Komisopoulou E, Zhu M, Vivanco I, Teitell MA, Wu H, Ribas A, Lo RS, Mellinghoff IK, Mischel PS, Graeber TG. PMID: 22735335; PMCID: PMC3397414.
      View in: PubMed   Mentions: 66     Fields:    Translation:HumansCells
    62. Receptor tyrosine kinases in cancer escape from BRAF inhibitors. Cell Res. 2012 Jun; 22(6):945-7. Lo RS. PMID: 22565288; PMCID: PMC3367528.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    63. Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. Cancer Discov. 2012 May; 2(5):414-24. Shi H, Moriceau G, Kong X, Koya RC, Nazarian R, Pupo GM, Bacchiocchi A, Dahlman KB, Chmielowski B, Sosman JA, Halaban R, Kefford RF, Long GV, Ribas A, Lo RS. PMID: 22588879; PMCID: PMC3594852.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCells
    64. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun. 2012 Mar 06; 3:724. Shi H, Moriceau G, Kong X, Lee MK, Lee H, Koya RC, Ng C, Chodon T, Scolyer RA, Dahlman KB, Sosman JA, Kefford RF, Long GV, Nelson SF, Ribas A, Lo RS. PMID: 22395615; PMCID: PMC3530385.
      View in: PubMed   Mentions: 271     Fields:    Translation:HumansCells
    65. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clin Cancer Res. 2012 May 01; 18(9):2502-14. Paraiso KH, Haarberg HE, Wood E, Rebecca VW, Chen YA, Xiang Y, Ribas A, Lo RS, Weber JS, Sondak VK, John JK, Sarnaik AA, Koomen JM, Smalley KS. PMID: 22351686; PMCID: PMC3398738.
      View in: PubMed   Mentions: 66     Fields:    Translation:HumansAnimalsCells
    66. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012 Jan 19; 366(3):207-15. Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, Reis-Filho JS, Kong X, Koya RC, Flaherty KT, Chapman PB, Kim MJ, Hayward R, Martin M, Yang H, Wang Q, Hilton H, Hang JS, Noe J, Lambros M, Geyer F, Dhomen N, Niculescu-Duvaz I, Zambon A, Niculescu-Duvaz D, Preece N, Robert L, Otte NJ, Mok S, Kee D, Ma Y, Zhang C, Habets G, Burton EA, Wong B, Nguyen H, Kockx M, Andries L, Lestini B, Nolop KB, Lee RJ, Joe AK, Troy JL, Gonzalez R, Hutson TE, Puzanov I, Chmielowski B, Springer CJ, McArthur GA, Sosman JA, Lo RS, Ribas A, Marais R. PMID: 22256804; PMCID: PMC3724537.
      View in: PubMed   Mentions: 338     Fields:    Translation:HumansAnimalsCTClinical Trials
    67. Combinatorial therapies to overcome B-RAF inhibitor resistance in melanomas. Pharmacogenomics. 2012 Jan; 13(2):125-8. Lo RS. PMID: 22256862; PMCID: PMC3383458.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    68. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS One. 2011; 6(12):e28973. Atefi M, von Euw E, Attar N, Ng C, Chu C, Guo D, Nazarian R, Chmielowski B, Glaspy JA, Comin-Anduix B, Mischel PS, Lo RS, Ribas A. PMID: 22194965; PMCID: PMC3237573.
      View in: PubMed   Mentions: 102     Fields:    Translation:HumansCells
    69. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011 Nov 23; 480(7377):387-90. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT, Salton M, Dahlman KB, Tadi M, Wargo JA, Flaherty KT, Kelley MC, Misteli T, Chapman PB, Sosman JA, Graeber TG, Ribas A, Lo RS, Rosen N, Solit DB. PMID: 22113612; PMCID: PMC3266695.
      View in: PubMed   Mentions: 617     Fields:    Translation:HumansAnimalsCells
    70. Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition. Cancer Res. 2011 Aug 01; 71(15):5067-74. Shi H, Kong X, Ribas A, Lo RS. PMID: 21803746; PMCID: PMC3149831.
      View in: PubMed   Mentions: 89     Fields:    Translation:HumansCells
    71. Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations. J Transl Med. 2011 May 24; 9:76. Niehr F, von Euw E, Attar N, Guo D, Matsunaga D, Sazegar H, Ng C, Glaspy JA, Recio JA, Lo RS, Mischel PS, Comin-Anduix B, Ribas A. PMID: 21609436; PMCID: PMC3152784.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCells
    72. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010 Dec 16; 468(7326):973-7. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS. PMID: 21107323; PMCID: PMC3143360.
      View in: PubMed   Mentions: 923     Fields:    Translation:HumansCells
    73. Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. J Transl Med. 2010 Apr 20; 8:39. Søndergaard JN, Nazarian R, Wang Q, Guo D, Hsueh T, Mok S, Sazegar H, MacConaill LE, Barretina JG, Kehoe SM, Attar N, von Euw E, Zuckerman JE, Chmielowski B, Comin-Anduix B, Koya RC, Mischel PS, Lo RS, Ribas A. PMID: 20406486; PMCID: PMC2876068.
      View in: PubMed   Mentions: 107     Fields:    Translation:HumansAnimalsCells
    74. Transforming growth factor-beta activation promotes genetic context-dependent invasion of immortalized melanocytes. Cancer Res. 2008 Jun 01; 68(11):4248-57. Lo RS, Witte ON. PMID: 18519684.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    Roger's Networks
    Concepts (313)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (36)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCLA Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version v3.1.0-868-g8ba5679c on PROFILES-PWEB01.

    Copyright © The Regents of the University of California